Does Q5151 require prior authorization?

Yes, Q5151 requires prior authorization (high confidence). Code explicitly requires prior authorization.

What is the Medicare reimbursement rate for Q5151?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

Backwork Sign up free

`Q5151`, Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg

HCPCS/CPT

Prior Authorization

Prior Auth Required

Code explicitly requires prior authorization (high confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

Document meningococcal immunization at least 2 weeks prior to the first eculizumab dose or a clinical justification that delaying eculizumab posed greater risk than meningococcal infection.
For PNH initiation, document flow cytometry confirming PNH and either evidence of clinically significant hemolysis or a documented history of a major adverse vascular event (MAVE) from thromboembolism.

Key Coverage Criteria

Eculizumab is covered for treatment of paroxysmal nocturnal hemoglobinuria (PNH) when flow cytometry confirms PNH and there is either evidence of clinically significant hemolysis or a documented history of a major adverse vascular event (MAVE) from thromboembolism.
Eculizumab is covered for treatment of atypical hemolytic uremic syndrome (aHUS) as an initial trial (generally 6–12 weeks) when the individual has no signs of STEC-HUS and thrombotic thrombocytopenic purpura (TTP) has been ruled out or a trial of plasma exchange did not produce clinical improvement.
Eculizumab is covered for biopsy-proven dense deposit disease when elevated serum sC5b-9 (sMAC) levels are documented.
Eculizumab may be covered for other label and off-label indications supported by recognized compendia or the FDA label when dose and frequency conform to FDA labeling or recognized compendia guidance.
Medically necessary for initial therapy of aHUS when: documentation ruling out STEC-HUS and TTP; diagnosis with signs of aHUS; treatment-naïve; FDA-labeled dosing for aHUS; prescribed by hematologist/nephrologist; initial authorization up to 12 months. Continuation requires positive clinical response and dosing per FDA labeling, with reauthorization up to 12 months.
Covered when hospital outpatient facility infusion services for specialty medications and IVIG/SCIG therapy are considered medically necessary and the member meets the specific clinical criteria described in the policy.

19 Active Policies

A54548, Billing and Coding: Eculizumab, and Biosimilars: EPYSQLI-eculizumab-aagh, and BKEMV-eculizumab-aeeb

NGS-J6-L33394, Drugs and Biologicals, Coverage of, for Label and Off-Label Uses

NGS-JK-L33394, Drugs and Biologicals, Coverage of, for Label and Off-Label Uses

HEALTHNET_OR-HNOR-ECULIZUMAB-SOLIRIS-ECULIZUMAB-AEEB-BKEMV-ECULIZUMAB-AAGH-FDBA3BF476, Eculizumab (Soliris), Eculizumab-aeeb (Bkemv), Eculizumab-aagh (Epysqli); CP.PHAR.97

MODA-SOLIRIS-ECULIZUMAB-AC7ACFD6DD, Eculizumab: Soliris; Bkemv; Epysqli

BCBSIL-ADM1001.034, Specialty Medication Administration Site of Care

BCBSMT-RX501.066, Eculizumab and Associated Biosimilar(s)

BCBSMT-ADM1001.034, Specialty Medication Administration Site of Care

BCBSNM-RX501.066, Eculizumab and Associated Biosimilar(s)

BCBSNM-ADM1001.034, Specialty Medication Administration Site of Care

BCBSOK-RX501.066, Eculizumab and Associated Biosimilar(s)

BCBSOK-ADM1001.034, Specialty Medication Administration Site of Care

UMR-POL-UMR-complement-inhibitors, Complement C5 Inhibitors

UMR-POL-UMR-provider-administered-drugs-soc, Provider Administered Drugs – Site of Care

SUREST-POL-SUREST-complement-inhibitors, Complement C5 Inhibitors

EVICORE-MEDICAL_DRUG-42D804718709, Eculizumab Products (Soliris, Bkemv, Epysqli)

UHC-POL-complement-inhibitors, Complement C5 Inhibitors

UHC-POL-provider-administered-drugs-soc, Provider Administered Drugs – Site of Care

BCBSIL-RX501.066, Eculizumab and Associated Biosimilar(s)

`Q5151`, Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

19 Active Policies

Related Codes

Have a follow-up question?

Q5151, Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

19 Active Policies

Related Codes

Have a follow-up question?

`Q5151`, Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg